- Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study. [Journal Article]
- DSDrug Saf 2018 Aug 16
- CONCLUSIONS: In this observational study, we observed likely causal associations between Stevens-Johnson syndrome/toxic epidermal necrolysis and use of allopurinol, cyclooxygenase-2 inhibitors, and 5-aminosalicylates, and potential associations for proton pump inhibitors, fluoxetine, and mirtazapine.
- The safety of beclomethasone dipropionate in the treatment of ulcerative colitis. [Journal Article]
- EOExpert Opin Drug Saf 2018 Aug 11
- Beclomethasone dipropionate (BDP) is a second-generation corticosteroid that use novel drug technologies to ensure colonic targeting and potentially reducing systemic corticosteroid concentrations. I...
Beclomethasone dipropionate (BDP) is a second-generation corticosteroid that use novel drug technologies to ensure colonic targeting and potentially reducing systemic corticosteroid concentrations. It is approved for treatment of patients with mild-to-moderate ulcerative colitis (UC) who do not respond to mesalazine. The gut-selective mechanism of action has the potential to improve the safety profile of beclomethasone dipropionate compared to other conventional corticosteroids. Areas covered: We reviewed the mechanism of action, efficacy and safety of beclomethasone dipropionate in the treatment of UC. The positioning of beclomethasone dipropionate in management algorithms is also discussed. Expert opinion: The highly selective mechanism of action of BDP restricts the steroid-related side-effects. BDP is efficacious in the treatment of active UC. Topical formulation is the first-choice in distal UC, while oral formulation is used in patients with an extensive involvement of the colon. The rates of adverse events (AE), serious AEs, and steroid-related side-effects are similar to placebo and mesalamine and slightly inferior to traditional corticosteroids.
- Enteral nutrition for maintenance of remission in Crohn's disease. [Review]
- CDCochrane Database Syst Rev 2018 Aug 11; 8:CD005984
- CONCLUSIONS: The results for the outcomes assessed in this review are uncertain and no firm conclusions regarding the efficacy and safety of enteral nutrition in quiescent CD can be drawn. More research is needed to determine the efficacy and safety of using enteral nutrition as maintenance therapy in CD. Currently, there are four ongoing studies (estimated enrolment of 280 participants). This review will be updated when the results of these studies are available.
- Pulmonary Involvement in Crohn's Disease: A Rare Case Report. [Journal Article]
- CCureus 2018 May 30; 10(5):e2710
- Crohn's disease (CD) is a granulomatous inflammatory disease that can involve any part of the gastrointestinal tract, from mouth to anus. In most cases, it remits and relapses in the terminal ileum, ...
Crohn's disease (CD) is a granulomatous inflammatory disease that can involve any part of the gastrointestinal tract, from mouth to anus. In most cases, it remits and relapses in the terminal ileum, requiring treatment via steroid boluses. In rare cases, however, CD can involve the pulmonary system presenting as dyspnea on exertion and dry cough. We present a case of a 38-year-old man who developed shortness of breath, cough, and wheezing for one month after a colectomy procedure due to recurrent toxic megacolon. He recovered and tolerated extubation successfully and was prescribed mesalamine as maintenance therapy for CD. His pulmonary symptoms after the colectomy, along with his imaging and pulmonary function tests, indicated pulmonary involvement in the lungs as a progression of the primary inflammatory bowel disease. After confirming this diagnosis, he was treated with oral high-dose steroids after successful diagnosis, and the patient's symptoms improved dramatically. This case highlights often overlooked CD bronchopulmonary involvement in the postoperative period.
- Colorectal cancer prevention in patients with ulcerative colitis. [Review]
- BPBest Pract Res Clin Gastroenterol 2018 Feb - Apr; 32-33:103-109
- Ulcerative colitis is characterized by chronic inflammation, which may lead to the accumulation of high levels of pro-inflammatory cytokines within the colonic mucosa, and thus to dysplastic lesions ...
Ulcerative colitis is characterized by chronic inflammation, which may lead to the accumulation of high levels of pro-inflammatory cytokines within the colonic mucosa, and thus to dysplastic lesions and cancer. Although the trend is decreasing, ulcerative colitis patients still have a 2.4 fold higher risk of colorectal cancer compared to the general population. The key task is to control colonic inflammation, and a rapid step-up approach while closely monitoring intestinal inflammation are recommented. Surveillance colonoscopy program demonstrated its efficacy for reducing the incidence of colorectal cancer in ulcerative colitis. The impact of medication on the reduction of colorectal cancer risk was hardly investigated and it remains unclear whether they have intrinsic anti-neoplastic properties or only downregulate inflammatory pathways. Several studies showed a decreased risk of colorectal cancer in ulcerative colitis patients treated with 5-aminosalicylic acid and chemoprevention with mesalamine compounds is currently recommended. The current level of evidence is too low for thiopurines and anti-TNFα agents. Large, prospective cohort studies are ongoing and are likely to bring new findings about the impact of drugs on colorectal cancer risk in the current era of biologics.
- Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. [Journal Article]
- JPJ Pediatr Gastroenterol Nutr 2018; 67(2):257-291
- CONCLUSIONS: These guidelines provide a guide to clinicians managing children with UC and IBD-unclassified management to provide modern management strategies while maintaining vigilance around appropriate outcomes and safety issues.
- Comparison table: some drugs for inflammatory bowel disease. [Journal Article]
- MLMed Lett Drugs Ther 2018 Jul 02; 60(1550):e117-e122
- Table: drugs for ulcerative colitis. [Journal Article]
- MLMed Lett Drugs Ther 2018 Jul 02; 60(1550):e114
- Drugs for inflammatory bowel disease. [Journal Article]
- MLMed Lett Drugs Ther 2018 Jul 02; 60(1550):107-114
New Search Next
- Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review. [Review]
- CJCan J Gastroenterol Hepatol 2018; 2018:7439730
- CONCLUSIONS: This literature review provided a comprehensive overview of the economic evaluations for the different treatment options for IBD over the past 12 years and represents a helpful reference for future economic evaluations.